LEO Pharma: Clinical Trials

60 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 68 Phase 2, 7 Phase 1, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	68	Completed 60, Terminated 4, Recruiting 2, Active not recruiting 1, Unknown 1
Phase 1	7	Completed 7
Phase 3	2	Completed 2

Follow LEO Pharma: new trials by email

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris Delgocitinib - Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris	Phase 2	Recruiting	Icahn School of Medicine at Mount Sinai	30	2026-05-19	2026-07-10
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis Delgocitinib cream, Vehicle cream - Palmoplantar Pustulosis	Phase 2	Recruiting	LEO Pharma	135	2025-09-11	2026-10-01
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis LEO 138559, Placebo - Atopic Dermatitis	Phase 2	Completed	LEO Pharma	262	2023-09-20	2026-02-12
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Tralokinumab - Atopic Dermatitis	Phase 2	Completed	LEO Pharma	28	2022-09-07	2026-05-14
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD LEO 138559, Dupixent® - Atopic Dermatitis	Phase 2	Completed	LEO Pharma	13	2022-05-19	2025-03-11
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia Delgocitinib cream, Delgocitinib cream vehicle - Frontal Fibrosing Alopecia	Phase 2	Completed	LEO Pharma	35	2022-04-19	2025-03-06
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis LEO 152020 tablet, LEO 152020 placebo tablet - Atopic Dermatitis	Phase 2	Completed	JW Pharmaceutical	216	2021-12-13	2024-06-04
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. LEO 138559, LEO 138559 placebo - Atopic Dermatitis	Phase 2	Completed	LEO Pharma	58	2021-07-14	2025-03-13
Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria LEO 152020, LEO 152020 placebo - Cholinergic Urticaria	Phase 2	Completed	JW Pharmaceutical	20	2021-05-10	2024-04-22
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis Isotretinoin, Vehicle - Congenital Ichthyosis	Phase 2	Completed	LEO Pharma	34	2019-12-03	2026-05-22
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. Delgocitinib cream, Delgocitinib cream vehicle - Discoid Lupus Erythematosus	Phase 2	Terminated	LEO Pharma	27	2019-07-09	2025-03-06
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Spesolimab - Generalized Pustular Psoriasis	Phase 2	Active not recruiting	LEO Pharma	131	2019-05-29	2026-09-01
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. Delgocitinib cream, Delgocitinib cream vehicle - Atopic Dermatitis	Phase 2	Completed	LEO Pharma	251	2018-12-28	2025-03-12
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema Delgocitinib cream, Delgocitinib cream vehicle - Chronic Hand Eczema	Phase 2	Completed	LEO Pharma	258	2018-11-28	2025-03-12
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) Tralokinumab, Placebo, Tdap vaccine - Atopic Dermatitis	Phase 2	Completed	LEO Pharma	215	2018-07-13	2025-03-11
Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate AFXl-assisted ingenol mebutate delivery - Carcinoma, Basal Cell	Phase 1 / Phase 2	Completed	Merete Haedersdal	20	2017-11-17	2018-07-10
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. LEO 124249, Ointment vehicle - Alopecia Areata	Phase 2	Terminated	LEO Pharma	13	2017-10-30	2025-02-24
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris LEO 32731, LEO 32731 Placebo - Psoriasis Vulgaris	Phase 2	Completed	LEO Pharma	36	2016-09-01	2017-08-28
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne LEO43204, Placebo - Acne Vulgaris	Phase 2	Completed	LEO Pharma	59	2016-06-01	2025-03-06
Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis LEO 124249 ointment 30 mg/g, LEO 124249 ointment vehicle - Inverse Psoriasis	Phase 2	Completed	LEO Pharma	69	2016-03-01	2025-02-24

Showing 20 of 68. Sign in to see all of them.

Conditions studied

Dermatitis, Atopic (9)  ·  Keratosis, Actinic (8)  ·  Psoriasis (6)  ·  Acne Vulgaris (2)  ·  Alopecia Areata (2)  ·  Impetigo (2)  ·  Rosacea (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Carcinoma, Basal Cell (1)  ·  Condylomata Acuminata (1)  ·  Dermatitis, Perioral (1)  ·  Disseminated Intravascular Coagulation (1)  ·  Hemorrhage (1)  ·  Ichthyosis Vulgaris (1)  ·  Kidney Failure, Chronic (1)

Interventions

calcipotriene (8)  ·  3-ingenyl angelate (4)  ·  Gels (4)  ·  LEO 43204 (3)  ·  Ointments (3)  ·  Tinzaparin (3)  ·  azelaic acid (3)  ·  betamethasone-17,21-dipropionate (3)  ·  2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (2)  ·  Betamethasone (2)  ·  Cromolyn Sodium (2)  ·  tralokinumab (2)  ·  Aerosolized Particles and Droplets (1)  ·  Aprepitant (1)  ·  Blood Specimen Collection (1)

Countries

United States (31)  ·  Canada (20)  ·  Germany (20)  ·  France (15)  ·  United Kingdom (9)  ·  Denmark (6)  ·  Poland (6)  ·  Australia (4)  ·  Japan (4)  ·  Spain (4)  ·  Czechia (3)  ·  Romania (3)  ·  Finland (2)  ·  Netherlands (2)  ·  Argentina (1)

Top investigators

Catherine Queille-Roussel, MD (2)  ·  Gary Goldenberg, MD (2)  ·  Alexander V Anstey, MD (1)  ·  Almena L Free, MD (1)  ·  Amy S Paller, MD (1)  ·  Benjamin Ungar, MD (1)  ·  C. William Hanke, MD (1)  ·  Catherine Mrs Queille-Roussel, MD (1)  ·  Colin Fleming, MD (1)  ·  Daniel M Siegel, MD (1)  ·  Daniel M Siegel, MD, MS (1)

Results publications

PMID 16458642, PMID 23986161, PMID 25708531, PMID 27995521, PMID 28264612, PMID 29399258, PMID 29399263, PMID 32785881, PMID 33687069, PMID 33779986, PMID 34397196, PMID 37170057, PMID 38189593, PMID 38308655, PMID 38485862, PMID 39428453, PMID 40186746, PMID 41101628

NIH funding

2014 (3), 2008 (2), 2018 (2), 2015 (1), 2017 (1), 2023 (1)